Objectives: To compare the intrinsic activity of pradofloxacin, a new fluoroquinolone developed for use in veterinary medicine, with other fluoroquinolones, against anaerobic bacteria isolated from dogs and cats.
Introduction
Quinolones were first described in the early 1960s, 1 with limited in vitro activity against Gram-negative species. Modifications to nalidixic acid in the 1970s gave rise to compounds that were generally used for oral treatment of urinary tract infections. Improvements in activity against Gram-negative and -positive pathogens followed the introduction of piperazine substitution at position 7 of the naphthyridine core and fluorination at position 6 of the molecule, this group being commonly referred to as the fluoroquinolones. Norfloxacin was the first member of this class. Substitution of a carbon atom for nitrogen resulted in ciprofloxacin, a 1-cyclopropanyl, and ofloxacin and levofloxacin, both 1,8-cyclo compounds; all three of these latter mentioned compounds have been classified as second-generation fluoroquinolones. 2 The next development included compounds such as moxifloxacin, resulting from a 7-azabicyclo modification that enhanced antibacterial activity and pharmacokinetic properties, consequently referred to as a third-generation fluoroquinolone. 2 While the spectrum of activity of the first-generation fluoroquinolones was essentially against Enterobacteriaceae, the secondgeneration fluoroquinolones have a wider spectrum including activity against many Gram-negative species (bacilli and cocci), some Gram-positive species, intracellular organisms (Rickettsia spp. and Mycobacterium spp.) and Mycoplasma spp. 3 -6 Thirdgeneration fluoroquinolones such as moxifloxacin have enhanced activity against Gram-positive bacteria relative to first-and second-generation compounds and good activity against anaerobes. 7 Fluoroquinolones substituted at position C-8 by a methoxy group such as moxifloxacin have been shown to have greatly improved bactericidal activity. 8, 9 Pradofloxacin is being exclusively developed for use in veterinary medicine. It is a third-generation fluoroquinolone structurally similar to moxifloxacin 2, 7 and can therefore be expected to show enhanced activity against Gram-positive organisms and anaerobes; this will differentiate pradofloxacin from earlier generation fluoroquinolone compounds used in veterinary medicine. It is structurally distinguished from enrofloxacin, the first veterinary fluoroquinolone, 10 by two elements: a bicyclic amine, S,S-pyrrolidino-piperidine, replacing the ethyl-piperazine moiety located at position C-7 of enrofloxacin, and a cyano group that is attached to the C atom at position 8 ( Figure 1 ). The increased potency of pradofloxacin is mainly attributed to the S,S-pyrrolidino-piperidine moiety at C-7, but the cyano group at C-8 extends activity to first-and second-step fluoroquinolone-resistant strains. Pradofloxacin has been shown to be highly active in vitro against aerobic clinical isolates from dogs and cats. Typical MIC 90 values for pradofloxacin against organisms such as Pasteurella multocida, Escherichia coli, Staphylococcus intermedius and Streptococcus spp. have been shown to be in the range 0.016 -0.25 mg/L.
11
Low mutant prevention concentrations (MPCs) have been reported for pradofloxacin against E. coli and Staphylococcus spp. 12 Low MPC has recently been reported also for one strain of the anaerobic bacterium Porphyromonas gingivalis. 13 Therefore, pradofloxacin should possess an exceptional potential in eliminating not only large populations of wild-type but also selected first-step resistant clones. 12 In order to evaluate its potential for use against anaerobes from cats and dogs, we studied the comparative activity of pradofloxacin relative to other fluoroquinolones used in companion animals against 141 anaerobic strains isolated in the period 2000 -2002.
Materials and methods

Bacterial strains
Anaerobic bacteria were isolated from oral infections, abscesses and wound infections and also from faecal flora of dogs and cats. A total of 141 strains were isolated from dogs (94) and cats (47) in the period 2000-2002, all of which were from the UK and obtained from animals that had not received antimicrobial agents for at least 3 months prior to sampling. Individual species were isolated from separate animals and thus all bacterial species can be considered as unrelated. Identification was to species level using the Biolog TM system (Hayward, CA, USA) and isolates were stored at 2808C prior to testing. The strains identified to species level were:
Hallella seregrens (1); Macrococcus bovicus (1), Megamonas hypermegale (2); Peptostreptococcus anaerobius (3); Porphyromonas [P. gingivalis (5), P. macacae (1)], Prevotella [P. buccae (1), P. corporis (2), P. dentalis (2), P. denticola (3), P. disiens (1), P. heparinolytica (1), P. oralis (7), P. oris (1), P. zoogleoformans (2)]; Propionibacterium [P. acnes (3), P. granulosum (1) P. propionicum (1)]; Rhodococcus fascians (1); Ruminococcus torques (2); Sebaldella termitidis (1); Selenomonas sputigena (2); Sporomusa [S. acidovorans (3), S. sphaeroides (3)]. There were a number of isolates for which species names could not be defined: Clostridum spp. (7), Bacteroides spp.
(1), Bifidobacterium spp. (1) spp. (1). Isolates were sub-cultured on Fastidious Anaerobe Agar (LabM, LAB103, Bury, UK) prior to susceptibility testing.
Susceptibility testing
The test compounds, pradofloxacin, marbofloxacin, enrofloxacin, ibafloxacin and difloxacin were all supplied with a certificate of analysis detailing purity. MICs of each of the test compounds against 141 anaerobic bacteria were determined using agar dilution methodology as described by the CLSI (formerly NCCLS) in complete accordance with the procedures detailed in M11-A5, Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria, using Brucella blood agar (Difco, D0964-17) supplemented with haemin (5 mg/L) and vitamin K1 (1 mg/L) and incubating for up to 48 h. 14 B. fragilis ATCC 25285 and Eubacterium lentum ATCC 43055 were used as quality control organisms. All susceptibility testing was carried out under strict anaerobic conditions using an anaerobic workstation (Don Whitley Scientific Limited, Shipley, UK).
Results and discussion
The MIC data for pradofloxacin and the other veterinary fluoroquinolones are summarized in Table 1 for all genera where n was 5, i.e. Clostridium, Bacteroides, Fusobacterium, Prevotella, Porphyromonas, Sporomusa and Propionibacterium. Comparative MIC data were also generated for species where n was between 2 and 4, namely Actinomyces where n ¼ 3 ( pradofloxacin, 0.125 -0.25; marbofloxacin, 0.5 -1; enrofloxacin, 0.25 -1; difloxacin, 1; ibafloxacin, 0.5 -2), Eubacterium, n ¼ 3 ( pradofloxacin, 0.25-0.5; marbofloxacin, 0.5 -2; enrofloxacin, 0.25 -4; difloxacin, 1 -2; ibafloxacin, 4), P. anaerobius, n ¼ 3 ( pradofloxacin, 0.25; marbofloxacin, 1; enrofloxacin, 1 -2; difloxacin, 2; ibafloxacin, 4), M. hypermegale, n ¼ 2 ( pradofloxacin, 1-2; marbofloxacin, 2 -16; enrofloxacin, 16 - 0.125; difloxacin, 0.125; ibafloxacin, 0.25), R. fascians ( pradofloxacin, 0.031; marbofloxacin, 0.062; enrofloxacin, 0.031; difloxacin, 0.062; ibafloxacin, 0.062) and S. termitidis ( pradofloxacin, 0.062; marbofloxacin, 1; enrofloxacin, 2; difloxacin, 1; ibafloxacin, 2). All individual strain MIC values are provided in Table S1 , available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/).
Pradofloxacin demonstrates enhanced activity relative to the other tested compounds, consistent with what would be expected from a third-generation fluoroquinolone. 15 -17 This is best expressed in Figure 2 where the total data set is presented as susceptibility distributions for the respective antimicrobial agents from which it can be seen that the mode MIC for pradofloxacin was 0.25 mg/L compared with 1 mg/L for marbofloxacin, 2 mg/L for enrofloxacin and difloxacin and 4 mg/L for ibafloxacin. Figure 2 also shows that all isolates were susceptible to pradofloxacin at 2 mg/L, whereas the MIC range extended to 32 mg/L for difloxacin and 64 mg/L for marbofloxacin, enrofloxacin and ibafloxacin.
Goldstein 18 emphasized that due to increasing development of resistance of anaerobic bacteria to all antimicrobial agents there is a need to find new agents active against anaerobes. Additionally, the point was made that it would be useful to have oral antimicrobial agents with broad-spectrum activity against both aerobes and anaerobes. Currently available fluoroquinolones in veterinary medicine only have modest activity against anaerobes, as evident from the data in Table 1 . It is clear that pradofloxacin has enhanced anaerobic activity and further provides broad-spectrum coverage against aerobic organisms.
11 While data supporting the activity of thirdgeneration fluoroquinolones against human isolates are available, such data have not previously been reported for animal isolates. Indeed, there has been contrasting data reported, suggesting that animal isolates may not be equally susceptible. In this context, Wexler et al. 19 reported that 96% of 557 anaerobes tested were susceptible to trovafloxacin at 2 mg/L; Goldstein et al. 20 showed trovafloxacin to be active against anaerobic pathogens isolated from human and animal bitewounds, all were susceptible at 2 mg/L with the exception of Fusobacterium spp., which were susceptible at 4 mg/L. The authors commented on this small one dilution difference in susceptibility of Fusobacterium spp. with the Wexler study 19 and pointed out that the same methods were used and the reason for the disparity was unclear except that they studied veterinary isolates recovered from human infections, whereas Wexler et al. 19 used human isolates from other sources. The data from our study suggest that animal isolates exhibit similar susceptibility as human isolates.
Moxifloxacin is probably the most relevant example of how third-generation fluoroquinolones demonstrate enhanced antianaerobe activity because it is structurally similar to pradofloxacin. Indeed, the reported MIC data for pradofloxacin are consistent with MIC data reported for moxifloxacin. 21 -23 This study provides the first comparative MIC data for veterinary fluoroquinolones against anaerobes isolated from dogs and cats and reveals a high level of anti-anaerobe activity for pradofloxacin. It is clear that third-generation fluoroquinolones, such as pradofloxacin, may have important utility in veterinary medicine as singledrug therapy for infections caused by mixed aerobic/anaerobic infections 15, 24 and in this context they could also be used to treat bacteria associated with dental infections as has been demonstrated in a large pan-European study investigating the in vitro activity of a range of anti-anaerobe antimicrobials against Gram-negative bacilli. 25 
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